Potential of silver against human colon cancer: (synthesis, characterization and crystal structures of xylyl (Ortho, meta, & Para) linked bis-benzimidazolium salts and Ag(I)-NHC complexes: In vitroanticancer studies)
Open Access
- 7 February 2013
- journal article
- Published by Springer Nature in BMC Chemistry
- Vol. 7 (1) , 27
Abstract
Background: Since the first successful synthesis of Ag(I)-N-heterocyclic carbene complex in 1993, this class of compounds has been extensively used for transmetallation reactions where the direct synthesis using other metal ions was either difficult or impossible. Initially, silver(I)-NHC complexes were tested for their catalytic potential but could not get fame because of lower potential compare to other competent compounds in this field; however, these compounds proved to have vital antimicrobial activities. These encouraging biomedical applications further convinced researchers to test these compounds against cancer. The current work has been carried out with this aim. Results: N-ipropylbenzimidazole was synthesized by reaction of benzimidazole with i propyl bromide. The subsequent treatment of the resulting N-alkylbenzimidazole with ortho/meta/para-(bromomethylene) benzene afforded corresponding bis-benzimidazolium bromides (5-7). The counter anion (Br-) of each salt was replaced by hexaflourophosphate (PF6 -) for the ease of handling and further purification (8-10). Each salt (Ligand), in halide form, was further allowed to react with Ag2O with stirring at room temperature for a period of two days to synthesize dinuclear Ag(I)-NHC complexes (11-13). All synthesized compounds were characterized by spectroscopic techniques and microanalysis. Molecular structures of compounds 5, 9 & 10 were established through single crystal x-ray diffraction technique. All the compounds were assessed for their anti-proliferation test on human colorectal cancer cell line (HCT 116). Results showed that the ligands (5-10) showed mild to negligible cytotoxicity on HCT 116 cells whereas respective silver complexes (11-13) exhibited dose dependent cytotoxicity towards the colon cancer cells with IC50 ranges between 9.7 to 44.5 μM. Interestingly, the complex 13 having para-xylyl spacer was found the most active (IC50 9.7 μM) that verifies our previously reported results. Conclusions: All the bis-benzimidazolium salts (8-10) were found inactive whereas after bonding with silver cations, the Ag(I)-NHC complexes (11-13) showed a dose dependent cytotoxic activity. This proved that silver practice an important role in death of cancer cells. Also, the N-alkyl/aryl substitutions and ortho/metal/para xylyl units regulate the cytotoxicity.Keywords
This publication has 42 references indexed in Scilit:
- Investigation of antibacterial properties silver nanoparticles prepared via green methodBMC Chemistry, 2012
- Design, synthesis and structural studies of meta-xylyl linked bis-benzimidazolium salts: potential anticancer agents against ‘human colon cancer’BMC Chemistry, 2012
- 3,3′-[1,2-Phenylenebis(methylene)]bis(1-ethyl-1H-benzimidazol-1-ium) bis(hexaflourophosphate)Acta Crystallographica Section E Crystallographic Communications, 2012
- 3,3′-[1,2-Phenylenebis(methylene)]bis(1-octylbenzimidazolium) dibromide monohydrateActa Crystallographica Section E Crystallographic Communications, 2012
- 3,3′-[1,2-Phenylenebis(methylene)]bis(1-ethylbenzimidazolium) dibromideActa Crystallographica Section E Crystallographic Communications, 2012
- 3,3′-[1,2-Phenylenebis(methylene)]bis(1-propylbenzimidazolium) dibromide hemihydrateActa Crystallographica Section E Structure Reports Online, 2012
- 3,3′-Di-n-propyl-1,1′-[p-phenylenebis(methylene)]diimidazolium dibromideActa Crystallographica Section E Crystallographic Communications, 2011
- 3,3′-[1,2-Phenylenebis(methylene)]bis(1-heptylbenzimidazolium) dibromide monohydrateActa Crystallographica Section E Structure Reports Online, 2011
- 3,3′-Dibenzyl-1,1′-(2,4,6-trimethyl-m-phenylenedimethylene)diimidazol-3-ium dibromideActa Crystallographica Section E Structure Reports Online, 2011
- Organometallic Anticancer CompoundsJournal of Medicinal Chemistry, 2010